Claude Chahine

The evolution of bispecific antibodies in multiple myeloma

Rebecca Ibrahim, Nadine Khalife, Ahmadreza Arbab, Annoir Shayya et autres

The treatment of multiple myeloma (MM) has revolutionized over the last decade with the advent of CD38-targeting monoclonal antibodies such as daratumumab and isatuximab that were integrated into the therapeutic arsenal of patients with newly diagnosed or with relapsed and/or refractory (R/R) …

fr, lb (code pays fourni par la source)

CN44 Improving the quality of end-of-life discussions in the International Oncology Department (IND) at Gustave Roussy: Insights and challenges

J. Pongerard, T.S. Assi, Z. Hoyau, Jorge Manuel Solano López Morel et autres

fr (code pays fourni par la source)

The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia

Khalil Saleh, Ahmadreza Arbab, Nadine Khalife, Rita Khoury et autres

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It is characterized by the clonal proliferation of mature B cells. The tumor microenvironment (TME) seems to play a crucial role in the survival and proliferation of tumor cells. Multiple new …

fr (code pays fourni par la source)

Updates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma

Khalil Saleh, Nadine Khalife, Ahmadreza Arbab, Rita Khoury et autres

CD19-targeting chimeric antigen receptor (CAR) T-cells have changed the treatment paradigm of patients with large B-cell lymphoma (LBCL). Three CAR T-cells were approved by the Food and Drug Administration (FDA) for patients with relapsed and/or refractory (R/R) LBCL in the third-line setting: …

fr (code pays fourni par la source)

The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma

Khalil Saleh, Rita Khoury, Nadine Khalife, Claude Chahine et autres

The advent of targeted therapies such as monoclonal antibodies, adoptive T-cell therapies, and antibody-drug conjugates (ADCs) dramatically changed the treatment landscape of diffuse large B-cell lymphoma (DLBCL) over the last two decades. Rituximab was the first one approved. Chimeric antigen receptor T-cells …

fr (code pays fourni par la source)

Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer

Khalil Saleh, Rita Khoury, Nadine Khalife, Claude Chahine et autres

Human epidermal growth factor 2 (HER2)-positive breast cancer (BC) represents nearly 20% of all breast tumors. Historically, these patients had a high rate of relapse and dismal prognosis. The advent of HER2-targeting monoclonal antibodies such as trastuzumab followed by pertuzumab had improved …

fr (code pays fourni par la source)

Zolbetuximab: A Potential Breakthrough in the Treatment Landscape of Gastric Cancer

Rebecca Ibrahim, Khalil Saleh, Rita Khoury, Nadine Khalife et autres

The incidence of gastric cancer has declined substantially over the last couple of years, especially in the USA and Western Europe; however, it is still considered to be a major global health probl...

fr (code pays fourni par la source)

1225P Combining ctDNA and tissue-based-genomic profiling in advanced cancer: A real-world evidence prospective study in non-Western patients treated at Gustave Roussy cancer campus

Tony Ibrahim, Tarek Assi, Rahma AbdElfattah Ibrahim, Rita Khoury et autres

fr (code pays fourni par la source)

1945P Diagnostic and therapeutic impact of liquid biopsy in soft tissue sarcomas: A case series

T.S. Assi, Tony Ibrahim, Rashid Ibrahim, Raya R. Khoury et autres

fr (code pays fourni par la source)

KRAS G12C mutation in metastatic colorectal cancer: a new target

Rebecca Ibrahim, Khalil Saleh, Claude Chahine, Rita Khoury et autres

“With deeper understanding of the intrinsic or acquired mechanisms of resistance to KRAS inhibition, especially in patients with mCRC, researchers continue to explore the clinical implications and ...

fr (code pays fourni par la source)

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy

Rebecca Ibrahim, Khalil Saleh, Claude Chahine, Rita Khoury et autres

One of the most important steps forward in the management of cancer was the discovery of immunotherapy. It has become an essential pillar in the treatment paradigm of cancer patients. Unfortunately, despite the various options presented with immune checkpoint inhibitors (ICIs), the …

fr (code pays fourni par la source)

Mechanisms of Resistance to Antibody-Drug Conjugates

Rita Khoury, Khalil Saleh, Nadine Khalife, Mohamad Ali Saleh et autres

The treatment of cancer patients has dramatically changed over the past decades with the advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and innovative T-cell therapy. Antibody-drug conjugates (ADCs) have also revolutionized the treatment of cancer. Several ADCs have already been approved …

fr, lb (code pays fourni par la source)